Document Classification

Section Type: RESULTS

Text: Statistically significant reductions also favored onabotulinumtoxinA/onabotulinumtoxinA for several secondary efficacy variables at week 56, including frequencies of migraine days (-11. 2 onabotulinumtoxinA/onabotulinumtoxinA, -10. 3 placebo/onabotulinumtoxinA ; P =. 018) and moderate/severe headache days (-10. 7 onabotulinumtoxinA/onabotulinumtoxinA, -9. 9 placebo/onabotulinumtoxinA ; P =. 027) and cumulative headache hours on headache days (-169. 1 onabotulinumtoxinA/onabotulinumtoxinA, -145. 7 placebo/onabotulinumtoxinA ; P =. 018).